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Abstract
Objective To develop a clinical risk prediction tool for
estimating the cumulative six month risk of death and death or
myocardial infarction to facilitate triage and management of
patients with acute coronary syndrome.
Design Prospective multinational observational study in which
we used multivariable regression to develop a final predictive
model, with prospective and external validation.
Setting Ninety four hospitals in 14 countries in Europe, North
and South America, Australia, and New Zealand.
Population 43 810 patients (21 688 in derivation set; 22 122 in
validation set) presenting with acute coronary syndrome with or
without ST segment elevation enrolled in the global registry of
acute coronary events (GRACE) study between April 1999 and
September 2005.
Main outcome measures Death and myocardial infarction.
Results 1989 patients died in hospital, 1466 died between
discharge and six month follow-up, and 2793 sustained a new
non-fatal myocardial infarction. Nine factors independently
predicted death and the combined end point of death or
myocardial infarction in the period from admission to six
months after discharge: age, development (or history) of heart
failure, peripheral vascular disease, systolic blood pressure,
Killip class, initial serum creatinine concentration, elevated
initial cardiac markers, cardiac arrest on admission, and ST
segment deviation. The simplified model was robust, with
prospectively validated C-statistics of 0.81 for predicting death
and 0.73 for death or myocardial infarction from admission to
six months after discharge. The external applicability of the
model was validated in the dataset from GUSTO IIb (global use
of strategies to open occluded coronary arteries).
Conclusions This risk prediction tool uses readily identifiable
variables to provide robust prediction of the cumulative six
month risk of death or myocardial infarction. It is a rapid and
widely applicable method for assessing cardiovascular risk to
complement clinical assessment and can guide patient triage
and management across the spectrum of patients with acute
coronary syndrome.
Introduction
Although patients with acute coronary syndrome share key
pathophysiological mechanisms, they present with diverse clini-
cal, electrocardiographic, and enzyme or marker characteristics
and experience a wide range of serious cardiovascular
outcomes.1 2 Estimated risk, based on clinical characteristics, is
challenging and imprecise, yet risk assessment is needed to guide
triage and key management decisions. Regulatory authorities
such as the National Institute for Health and Clinical Excellence
(NICE) and guideline groups recommend treatments according
to specific clinical and risk groupings, and trials show that certain
benefits may be predominantly or exclusively restricted to higher
risk patients with coronary syndrome.2–4 Binary methods of
stratifying risk (for example, normal or raised troponin concen-
tration or abnormal or normal findings on electrocardiography)
lack sufficient precision.5–11 To provide more accurate prognostic
information, and to target treatment more appropriately, more
precise yet user friendly risk stratification is required. To ensure
general applicability, risk stratification methods should be
derived from unrestricted populations that are representative of
patients with acute coronary syndrome in the real world12 and
should use widely available clinical variables.
The large multinational observational global registry of acute
coronary events (GRACE) has been used to derive regression
models to predict death in hospital13 and death after discharge14
in patients with acute coronary syndrome. However, a
comprehensive risk model is required to predict the cumulative
risk of death and death or myocardial infarction during the high
risk first six months after initial presentation with acute coronary
syndrome, the period when most complications occur.15 16
Because triage and management decisions are required within
the first hours or days after initial presentation we derived a risk
tool from characteristics of patients with acute coronary
syndrome at initial presentation.
Methods
GRACE methods and design
Full details of the GRACE rationale and methods have been
published elsewhere.17 18 The registry was designed to reflect an
unbiased population of patients with acute coronary syndrome
in 94 hospitals in 14 countries. All cases were assigned to one of
the following categories: ST segment elevation myocardial
infarction, non-ST elevation myocardial infarction, or unstable
angina (see appendix on bmj.com for inclusion criteria and
Full details of inclusion criteria and standard definitions can be found on
bmj.com.
Cite this article as: BMJ, doi:10.1136/bmj.38985.646481.55 (published 10 October 2006)
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standard definitions). Trained coordinators collected data using
standardised case report forms.
Statistical methods
We used two primary end points: all cause death or the compos-
ite measure of death or non-fatal myocardial infarction during
admission to hospital or after discharge (presentation to six
months).
We have summarised the distributions of continuous
variables with medians and 25th and 75th centiles and reported
the categorical variables as frequencies and percentages. Events
that occurred after six months were censored. Table 1shows the
variables included in the analysis from hospital admission to six
month follow-up. We used a Cox regression model to compute
crude hazard ratios and 95% confidence intervals to examine the
individual relation between each predictor and death and death
or myocardial infarction during follow-up (0 to 6 months).
We entered all demographic and clinical variables identified
by the crude regression analysis into the stepwise multiple Cox
regression (backward) analysis to produce final models for
predicting death and death or myocardial infarction. Only those
variables associated with an  ≤ 0.05 were retained; all variables
in the final model met the assumptions for proportional hazards.
No imputation was performed in these final models. Imputation
was tested but did not influence the identification of
multivariable predictors or the discriminative power of the
model for predicting death.13 The discriminative power of the
final models was assessed by the mean of the area under the
receiver operating characteristic (ROC) curve (C-statistic). The
curve is a measure of the discriminating ability of the risk model
and is a plot of sensitivity versus 1 − specificity. Accuracy of cali-
bration was evaluated by plotting the predicted versus the
observed mortality according to population tenths of predicted
risk. The model was tested prospectively in a separate dataset in
GRACE (n = 22 122) and also in an independent external data-
set, the GUSTO IIb (global use of strategies to open occluded
coronary arteries IIb) dataset,19 comprising the entire spectrum
of patients with acute coronary syndrome (12 142 patients, 4131
with ST elevation myocardial infarction, 8011 with non-ST
elevation myocardial infarction). The analysis was performed
with SAS software package (version 8.2, SAS Institute, Cary, NC)
and S-Plus (MathSort, Seattle, WA).
Results
Study population
The derivation population comprised 26 267 patients with
suspected acute coronary syndrome enrolled between 1 April
1999 and 30 September 2002. We excluded patients found to
have a non-cardiac or non-acute coronary cardiac diagnosis (fig
1). We also excluded patients transferred into a study hospital
because they lacked some baseline information and their
inclusion may also have led to bias because of morbidity associ-
ated with the indications for transfer. The study population
therefore comprised 21 688 patients of whom 19 931 were alive
at six month follow-up.
A total of 1757 (9.1%) deaths occurred, 1046/21 573 in hos-
pital (4.9% among patients with a diagnosis of acute coronary
syndrome on admission) and 711/15 265 during the period
after discharge (4.7%). We had no information on mortality (in
hospital or after discharge) for 51 patients. In the derivation set,
3110 (15.8%) patients died (n = 1757) or experienced a non-fatal
myocardial infarction (n = 1353) between presentation and six
month follow-up.
Table 1 Factors associated with death and death or myocardial infarction
(MI) from hospital admission to six month follow-up (hazard ratios and
95% confidence intervals)
Predictors 2 Death model 2 Death/MI model
Demographics
Age (per 10 year
increase)
915.3 1.34 (1.31 to 1.36) 345.4 1.13 (1.11 to 1.15)
Male 73.9 0.7 (0.60 to 0.72) 15.5 0.9 (0.80 to 0.93)
Weight (per 1 kg
increase)
133.2 0.98 (0.97 to 0.98) 30.9 0.99 (0.990 to 0.995)
Height (per 1 cm
increase)
59.0 0.98 (0.97 to 0.98) 21.1 0.99 (0.987 to 0.995)
Medical history
Angina 7.5 0.9 (0.80 to 0.96) 17.2 0.9 (0.80 to 0.92)
Smoking 65.2 0.7 (0.61 to 0.74) 34.1 0.8 (0.75 to 0.87)
Stroke 69.2 1.8 (1.56 to 2.10) 36.5 1.4 (1.26 to 1.58)
Diabetes 61.2 1.5 (1.36 to 1.67) 29.4 1.2 (1.15 to 1.35)
Coronary artery disease 13.4 0.8 (0.72 to 0.91) 78.1 0.7 (0.63 to 0.74)
Myocardial infarction 18.5 1.2 (1.13 to 1.37) 1.0 1.0 (0.96 to 1.12)
Congestive heart failure 373.6 3.0 (2.66 to 3.32) 142.8 1.8 (1.65 to 2.00)
Peripheral vascular
disease
91.0 1.9 (1.64 to 2.12) 33.7 1.4 (1.23 to 1.52)
Hypertension 30.8 1.3 (1.20 to 1.47) 4.0 1.1 (1.00 to 1.16)
Hyperlipidaemia 109.6 0.6 (0.52 to 0.64) 104.9 0.7 (0.63 to 0.73)
Atrial fibrillation 152.8 2.3 (2.00 to 2.60) 46.9 1.5 (1.33 to 1.66)
Renal dysfunction 129.5 2.2 (1.90 to 2.50) 25.8 1.3 (1.20 to 1.50)
PCI 42.8 0.6 (0.49 to 0.68) 67.4 0.6 (0.55 to 0.69)
CABG 3.1 0.9 (0.75 to 1.02) 22.6 0.8 (0.68 to 0.85)
Positive exercise
tolerance test
22.1 0.6 (0.54 to 0.77) 37.3 0.7 (0.58 to 0.75)
Bleeding 27.1 2.1 (1.60 to 2.77) 4.3 1.3 (1.02 to 1.79)
Delay in admission 0.1 1.0 (1.00 to 1.00) 0.9 1.0 (1.00 to 1.00)
Presentation characteristics
Pulse 286.8 1.02 (1.01 to 1.02) 177.4 1.01 (1.009 to 1.012)
Diastolic blood pressure 261.2 0.98 (0.98 to 0.98) 66.9 0.99 (0.989 to 0.993)
Systolic blood pressure 278.2 0.99 (0.98 to 0.99) 134.5 0.99 (0.991 to 0.994)
Killip class 1318.5 2.6 (2.47 to 2.74) 658.7 1.9 (1.80 to 1.98)
Cardiac arrest 306.6 5.5 (4.52 to 6.62) 230.6 3.8 (3.21 to 4.50)
Initial cardiac markers 246.1 2.2 (1.97 to 2.40) 375.7 2.1 (1.94 to 2.24)
Initial serum creatinine 334.2 1.3 (1.25 to 1.32) 125.1 1.2 (1.15 to 1.21)
Findings on electrocardiography
ST elevation 112.3 1.7 (1.52 to 1.84) 276.6 1.8 (1.72 to 1.98)
ST depression 95.8 1.6 (1.47 to 1.78) 95.5 1.4 (1.34 to 1.54)
ST segment deviation 215.1 2.2 (1.98 to 2.45) 294.2 2.0 (1.84 to 2.14)
T wave inversion or
pseudonormalisation
31.8 0.7 (0.65 to 0.81) 34.6 0.8 (0.72 to 0.85)
ST elevation anterior 105.8 1.8 (1.56 to 1.97) 138.3 1.7 (1.52 to 1.79)
ST elevation inferior 13.0 1.2 (1.10 to 1.40) 88.4 1.5 (1.37 to 1.62)
ST depression anterior 58.0 1.6 (1.39 to 1.75) 75.4 1.5 (1.35 to 1.60)
ST depression inferior 16.3 1.4 (1.17 to 1.59) 24.9 1.3 (1.19 to 1.50)
No of leads with ST
elevation
144.8 1.5 (1.37 to 1.56) 284.4 1.5 (1.44 to 1.58)
No of leads with ST
depression
97.8 1.4 (1.28 to 1.44) 86.0 1.2 (1.19 to 1.30)
Any significant Q wave 63.6 1.5 (1.37 to 1.67) 40.4 1.3 (1.19 to 1.39)
Left bundle branch block 82.7 2.1 (1.79 to 2.47) 32.2 1.5 (1.30 to 1.70)
Right bundle branch
block
56.4 1.9 (1.58 to 2.17) 18.2 1.3 (1.17 to 1.54)
Other changes 168.8 2.1 (1.89 to 2.33) 84.0 1.5 (1.40 to 1.68)
Previous use of medical therapy
Anti-arrhythmic drugs 16.9 1.7 (1.30 to 2.11) 0.1 1.0 (0.83 to 1.27)
Oral/topical nitrates 17.2 1.3 (1.13 to 1.39) 3.0 0.9 (0.85 to 1.01)
Aspirin 4.1 0.9 (0.82 to 0.99) 41.8 0.8 (0.73 to 0.84)
ACE inhibitors 20.5 1.3 (1.15 to 1.41) 0.01 1.0 (0.92 to 1.08)
Calcium channel blocker 10.1 1.2 (1.07 to 1.35) 1.0 1.0 (0.87 to 1.04)
Statins 55.8 0.6 (0.52 to 0.68) 89.8 0.6 (0.57 to 0.69)
PCI=percutaneous coronary intervention; CABG=coronary artery bypass grafting;
ACE=angiotensin converting enzyme.
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Early risks were highest for patients with ST segment
elevation myocardial infarction but by six months the risk of
death was similar to those with non-ST segment elevation myo-
cardial infarction (fig 2). Of those who survived to six months
after discharge, 36.2% (258/711) presented with ST segment
elevation myocardial infarction compared with 50.0% (880/
1757) of those who died during admission or follow-up. Raised
cardiac markers were detected in 35.0% (6883/19688) of those
who survived compared with 53.2% (905/1701) of those who
died.
Validation population
The validation set comprised 22 122 patients enrolled in this
multinational registry between 1 October 2003 and 30 Septem-
ber 2005. A total of 1730 (9.0%) patients died between hospital
admission and six month follow-up, 948 in hospital (4.3% among
patients with an admission diagnosis of acute coronary
syndrome) and 782 (5.4%) after discharge. No information on
mortality was available for 38 patients. In total, 2720 patients
died (n = 1730) or experienced a non-fatal myocardial infarction
(n = 990) between presentation and six month follow-up.
Predictors of mortality
From admission to six month follow-up, Killip class20 and
advanced age were the most powerful predictors of death in the
univariable analysis (table 1). Table 1 also shows the other base-
line characteristics and clinical parameters that predicted death
or death or myocardial infarction.
After multivariable analysis, the highest hazard ratios for
death were cardiac arrest on admission and increasing age.
These two key prognostic factors were closely followed by raised
cardiac markers or enzyme activity and ST segment deviation
(table 2).
Risk models predicting death and death or myocardial
infarction
The risk model comprises 14 predictors of death and 12 predic-
tors of death or myocardial infarction. The predictive accuracy of
the model was good, with C-statistics of 0.82 for death in hospi-
tal and 0.70 for death or myocardial infarction in hospital (table
3). Nine factors independently predicted death and the
combined end point in the period from admission to six months
after discharge: age, congestive heart failure, peripheral vascular
disease, systolic blood pressure, Killip class, initial serum
creatinine concentration, positive initial cardiac markers, cardiac
arrest on admission, and number of leads with ST deviation. The
highest hazard ratio for adverse outcome was for cardiac arrest
(tables 1 and 2).
Prospective and external validation of the GRACE risk score
When we tested the risk model in the prospective validation set,
it had excellent predictive accuracy for death (C-statistic = 0.81,
simplified model) and death or myocardial infarction
(C-statistic = 0.73).The predictive accuracy was maintained
across the acute coronary syndrome subgroups (table 3).
We validated the model externally using the GUSTO IIb
dataset of 12 142 patients with acute coronary syndrome. There
was excellent discrimination despite the fact that one of the key
parameters was not recorded in GUSTO IIb (cardiac arrest). The
C-statistic for the death model in all patients was 0.82
(C-statistics = 0.80 for ST segment elevation myocardial infarc-
tion and 0.76 for non-ST segment elevation myocardial
infarction).
Development of a simplified nomogram for clinical
application
We reduced the overall models to include the most important
variables that contained most ( > 90%) of the predictive informa-
Patients with suspected acute coronary syndrome (n=26 267)
GRACE risk score dataset (n=21 688)
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Death from hospital discharge to 6 months
Fig 2 Overall risk of death in hospital, from hospital admission to six months
after discharge (patients separated into unstable angina, non-ST segment
elevation myocardial infarction, and ST segment elevation myocardial infarction),
and from hospital discharge to six months
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tion. This nomogram retained excellent discriminant character-
istics based on eight variables and was used for the calculation of
risk (fig 3).
Discussion
The GRACE risk prediction tool (simplified nomogram)
includes variables that are readily available to clinicians even in
smaller community hospitals. It provides a novel and widely
applicable method of assessing the cumulative six month risk of
death and death or myocardial infarction across the spectrum of
patients admitted to hospital with acute coronary syndrome.
Accurate longer term assessment of risk is important because
most cardiac ischaemic events occur within the first few weeks
after initial presentation with acute coronary syndrome.15 16 Our
findings, based on 48 389 patients, support the validity of the
GRACE models for mortality in hospital and after discharge,14
which were derived from data from about 11 000 and 15 000
patients, respectively.
The need for risk prediction in patients with acute coronary
syndrome
In clinical practice, initial stratification of patients aims to identify
those suitable for reperfusion therapy (on the basis of a clinical
syndrome and ST segment elevation or other electrocardio-
graphic markers of acute infarction). Binary approaches are
commonly applied among others with acute coronary
syndrome, but separating patients based on one or two
characteristics may substantially overestimate or underestimate
the risk of death or myocardial infarction. There is therefore a
need for one predictive instrument that performs well in all
patients with acute coronary syndrome.
Robust evidence and practice guidelines (including NICE)
suggest that interventional and pharmacological therapies
predominantly benefit patients at higher risk.2 3 21 Despite the
availability of such guidelines, identification of patients at high
risk of cardiac ischaemic events remains challenging.22 23 In addi-
tion, the triage of patients into high intensity care units (cardiac
care units) is based predominantly on the criteria for reperfusion
therapy rather than risk in the patient. For example, a 55 year old
woman (blood pressure 142/80 mm Hg; heart rate 88 per
minute) who presents with ST elevation and raised troponin
concentration but without complications of a myocardial infarc-
Table 2 Final risk models predicting death and death or myocardial
infarction from hospital admission to six month follow-up (hazard ratios and
95% confidence intervals)
Predictors 2 Death model 2 Death/MI model
Age (per 10 year increase) 505.7 1.8 (1.68 to 1.84) 176.3 1.25(1.21 to 1.29)
Medical history:
Congestive heart failure 34.2 1.5 (1.32 to 1.73) 22.1 1.3
(1.17 to 1.45)
Hypertension 8.8 1.2 (1.05 to 1.33) —
Peripheral vascular disease 21.8 1.4 (1.21 to 1.62) 10.5 1.2
(1.08 to 1.36)
PCI 8.3 0.8 (0.64 to 0.93) —
Presentation characteristics:
Pulse (per 30 beats/min
increase)
44.3 1.2 (1.16 to 1.31) —
Systolic blood pressure (per
20 mm Hg decrease)
152.0 1.2 (1.22 to 1.30) 52.9 1.1
(1.07 to 1.13)
Killip class20 (per level
increase)
142.8 1.5 (1.41 to 1.62) 126.2 1.4
(1.30 to 1.46)
Initial serum creatinine (per
88 mol/l* increase)
135.3 1.2 (1.19 to 1.29) 41.1 1.1
(1.08 to 1.16)
Initial cardiac markers or
enzymes
63.0 1.6 (1.42 to 1.78) 184.3 1.7
(1.60 to 1.87)
Cardiac arrest 58.5 2.6 (2.00 to 3.32) 55.4 2.2
(1.76 to 2.63)
Findings on electrocardiography:
ST segment deviation 46.8 1.6 (1.41 to 1.88) —
Left bundle block branch 10.0 1.3 (1.10 to 1.60) —
No of leads with ST segment
elevation or depression
20.1 1.2 (1.10 to 1.33) 158.4 1.4
(1.34 to 1.49)
ST depression, anterior — 36.2 1.3
(1.22 to 1.47)
ST depression, inferior — 10.8 1.2
(1.09 to 1.40)
Other changes — 7.2 1.1
(1.04 to 1.27)
Hosmer and Lemeshow




*Equivalent to 1 mg/dl.
Table 3 C-statistics for validation of the full model and the simplified model
(as used for the nomogram) for all GRACE patients and for acute coronary
syndrome subgroups
All patients STEMI Unstable angina/ NSTEMI
All GRACE patients
Death:
Full model 0.82 0.82 0.81
Simplified model 0.81 0.82 0.79
Death or myocardial infarction:
Full model 0.70 0.66 0.71
Simplified model 0.70 0.66 0.70
Transferred patients
Death:
Full model 0.83 — —
Simplified model 0.83 — —
Death or myocardial infarction:
Full model 0.71 — —
Simplified model 0.70 — —
Model validation*
Death:
Full model 0.82 0.83 0.81
Simplified model 0.81 0.82 0.81
Death or myocardial infarction:
Full model 0.73 0.73 0.73
Simplified model 0.73 0.73 0.73
STEMI=ST segment elevation myocardial infarction; NSTEMI=non-ST segment elevation
myocardial infarction.
*On subsequent patients with acute coronary syndrome (22 122 enrolled between 1 October
2003 and 30 September 2005).
Age Years Cardiac arrest at admission
At Admission (in-hospital/to 6 months) At Discharge (to 6 months)

















Fig 3 GRACE risk calculator for death or myocardial infarction from admission to
hospital to six months after discharge with the simplified model
(www.outcomes.org/grace)
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tion (normal creatinine concentration, no heart failure) has a
probability of death of only 3% in the next six months. However,
a 55 year old woman with non-ST segment elevation myocardial
infarction (blood pressure 118/68; heart rate 92 per min) with
mild heart failure and raised creatinine concentration has a six
month risk of death of 16%. Without formal risk stratification,
the second patient would probably be managed in a low intensity
ward area and the management on discharge may not reflect the
risk in the patient.
Resolving intermediate risk
Despite similarities in key pathophysiological mechanisms, the
characteristics on presentation of patients with acute coronary
syndrome depend on the extent of the ischaemic territory (influ-
enced by acute thrombotic risk) and previous risk features (such
as older age, heart failure, and renal insufficiency). Whereas
patients with high risk features, including cardiogenic shock and
heart failure, are relatively straightforward to identify, most
patients lie in the intermediate range and risk is less obvious
(table 4). This intermediate range encompasses up to 10-fold dif-
ferences in the risk of death. Binary approaches, including those
that require separation of patients into high or low risk, are not
accurate enough for most patients in the middle range.2 3 We
propose that an appropriate instrument for risk prediction
needs to be applicable across the spectrum of acute coronary
syndrome, should be derived from a representative and broadly
based population, and needs to use variables that are readily
available to most clinicians shortly after the patient arrives at
hospital.
How does the present model differ from previous methods
of risk stratification?
Several other multivariable prognostic models have been
developed,5–10 24–28 most of which were derived from clinical trial
databases or specific subgroups of patients with acute coronary
syndrome. Patients with complications and comorbidity tend to
be excluded from such trials, thus limiting applicability in clinical
practice. Models developed from large claims databases are
potentially subject to bias.8 11 In contrast, the GRACE registry
spans the spectrum of acute coronary syndrome and is based on
an unselected contemporary population.
A C-statistic of less than 0.70 has been suggested to be of
limited clinical value.12 The TIMI (thrombolysis in myocardial
infarction) model performs well in patients who are eligible for
reperfusion therapy but is less effective in more general patients,
including those who are ineligible for reperfusion
(C-statistic = 0.65).24 An independent study suggests that the
unselected GRACE mortality model is superior to either the
TIMI or the PURSUIT (platelet glycoprotein IIb/IIIa in unstable
angina: receptor suppression with eptifibatide) models.29 We
have shown that the cumulative (0 to six month) GRACE risk
model performs well across the spectrum of acute coronary syn-
drome and has prospective and external validity. External valida-
tion with the GUSTO IIb dataset confirms the discriminant
characteristics of the model when applied to patients with ST
segment elevation myocardial infarction and those with non-ST
segment elevation myocardial infarction. Although we excluded
transferred patients from the derivation of this model (because
such patients may lack data for several baseline characteristics),
testing the model in the transfer dataset confirmed its applicabil-
ity to such patients (C-statistic = 0.83 for predicting death and
0.70 for predicting myocardial infarction, simplified model).
Simplified risk calculation for clinical application
The simplified model includes most the predictive information:
> 92% of the total model 2 for death and > 90% for death or
myocardial infarction (fig 3). The GRACE risk calculator (fig 3)
(available at www.outcomes.org/grace) can be used to derive a
prognostic score and to estimate the risk of clinically important
end points—death or the combined risk of death or myocardial
infarction—in individual patients. For ease of use, this nomogram
can be installed into a handheld device or personal computer
(data entry takes about 30 seconds) and is also available as a
score card.14
Limitations
GRACE is designed to enrol an unselected and generalisable
population of patients, though some participating centres are
required to obtain informed consent from patients before enrol-
ment. Therefore some patients who died early or who
experienced major clinical complications immediately on arrival
in hospital may be under-represented. The model may not be
appropriate for stratifying low risk patients with non-specific
chest pain without acute coronary syndrome, but such patients
do not require the same therapeutic and management decisions
as those with acute coronary syndrome.
We thank the physicians and nurses who participated in GRACE. The risk
calculator is available together with further information about the project
Table 4 Resolving intermediate risk (examples). Which patient has higher
risk of death or death or myocardial infarction? Is most of risk in hospital or
later?
Variable Example 1 Example 2 Example 3
Sex Female Male Female
Age (years) 49 60 62
Heart rate (bpm) 109 94 90
Systolic BP (mm Hg) 100 110 114
Creatinine (mol/l ) 104 71 106
Killip class II I II




Troponin T (g/l) <0.1 1.5 2.0
Death in hospital (death at six
months)
1% (2%) 2% (7%) 5% (12%)
Death or MI at six months 12% 22% 31%
BP=blood pressure; bpm=beats per minute; MI=myocardial infarction.
What is already known on this topic
Specific treatments are indicated in higher or lower risk
patients with acute coronary syndrome
Conventional clinical assessment and binary methods for
predicting risk based on results of electrocardiography and
markers of injury are not sufficiently accurate
Previous risk models were based on subgroups of patients
with acute coronary syndrome and were derived from large
clinical trials or healthcare claims databases
What this study adds
The GRACE risk tool can be used to predict the cumulative
risk of death and death or myocardial infarction in the
period from admission to hospital to six months after
discharge
The tool is simple to apply, robust, externally validated, and
applicable to patients across the complete spectrum of
acute coronary syndrome
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and the complete list of participants from www.outcomes.org/grace. We
thank Sophie Rushton-Smith for editorial services.
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